ArticleCancer reports (Hoboken, N.J.)2024
Incidence Trends of Vulvar Cancer in the United States: A 20-Year Population-Based Study.
Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Spatio-temporal inequalities in vulvar cancer mortality in Spain, 1999-2023: a nationwide Bayesian analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The impact of absent vulvar cancer screening guidelines on outcomes of vulvar squamous cell carcinoma: a national cancer database study.Cancer causes & control : CCC · 2026Article
- Gynecologic radiation oncology practice: retrospective analysis of a tertiary radiotherapy referral center.Frontiers in oncology · 2026Article
- Incidence and survival of vulvar and vaginal cancers in a province of Northern Italy: a population-based study.Gynecologic oncology reports · 2025Article
- Vulvar Squamous Cell Carcinoma: A Retrospective Analysis of Epidemiologic Characteristics, HPV Status, and Surgical Outcomes in 35 Cases.Life (Basel, Switzerland) · 2025Article
- Association between body mass index, obesity, and vulvar cancer recurrence.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Trend, Epidemiology, and Clinical Characteristics of Vulvar Cancers in Lagos, Nigeria: A Facility-Based Study.Cureus · 2025Article
- Controversies in vulvar cancer: revisiting the margin of error.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025Review
- Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma CellsIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite being uncommon, vulvar cancer is a serious health concern with a 5-year relative survival rate of 71%.
aimsThe objective was to investigate the incidence rates of this disease across different racial, ethnic, and histological subgroups in the United States, as well as the effects of the COVID-19 pandemic on this cancer.
methodsWe used the Surveillance, Epidemiology, and End Results (SEER) 22 database. The International Classification of Diseases for Oncology Version 3 topologic code C51 was assigned for vulvar cancer. Average annual percent change (AAPC) and the pairwise comparison with the parallelism and coincidence were reported. Counts and age-adjusted incidence rates per 100 000 individuals with their corresponding 95% confidence intervals (CIs) were reported.
resultsThe age-adjusted incidence rate of vulvar cancer was 2.40 (95% CI, 2.38-2.43) over the period 2000-2019, with an AAPC of 0.80 (95% CI, 0.63-0.99). By race/ethnicity, only non-Hispanic Whites had an increasing trend over 2000-2019 (AAPC: 1.30; 95% CI, 1.07-1.54). The highest age-adjusted incidence rate of vulvar cancer in the United States was for squamous cell carcinoma (SCC). There was a significant decrease in the age-standardized incidence rate of vulvar cancer in all races/ethnicities in all age groups (AAPC: -10.15; 95% CI, -15.35 to -4.94) over 2019-2020. Also, the incidence rates and incident numbers of vulvar cancer increased with aging and peaked at the 85+ age group.
conclusionThere was an increase in the incidence rate of vulvar cancer in all races, with a significantly increased trend in non-Hispanic White women from 2000 to 2019. SCC displayed the highest incidence rate among vulvar cancer histological types. It is recommended to conduct further research to identify the relevant risk factors of vulvar cancer in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.